AB185. Clinical and pathological features of sarcomatoid carcinoma of the renal pelvis and literature review

AB185. 肾盂肉瘤样癌的临床病理特征及文献综述

阅读:2

Abstract

OBJECTIVE: To explore the clinical, pathology, and prognosis of sarcomatoid carcinoma of the renal pelvis. METHODS: A case of the diagnosis and treatment of sarcomatoid carcinoma of the renal pelvis in our hospital were retrospectively analyzed. Articles were searched from the full-text databases, such as NCBI and PUBMED, the dates of clinical and pathology was collected from the satisfied articles, the feature of clinical, pathology and prognosis were summarized. RESULTS: Thirty-nine articles were screened, after screening, only 15 articles met the inclusion criteria, total 32 cases were included, combined with our center, 33 cases were included in the final analyzed. Most patients with sarcomatoid carcinoma of the renal pelvis are diagnosed because of abdominal pain and hematuria, most of them pathology ≥T2, according to the TNM classification system, most of the patients have radical prostatectomy. According to univariable Cox model, Not yet considered whether the impact of the prognosis of patients with follow-up treatment of the patients, 6 cases were recurrence, The median time to recurrence was three months, a total of 13 patients died, with a median time to death was seven months. Univariate analysis showed that patients’ gender, age, region, metastasis, tumor size, pathological stage has no effect on the prognosis of patients. CONCLUSIONS: Most likely resulting from the advanced stage of the disease at diagnosis and a poor response to systemic therapy. The present analysis suggests a poor prognosis for the majority of sarcomatoid carcinoma of the renal pelvis patients. To improve the survival rate of RPSC, it is therefore essential to perform an early diagnosis and early radical surgery.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。